glp 1 same as semaglutide GLP-1 vs. GLP-1 + GIP: What's the Difference for your Metabolism? Semaglutide GLP-1 for Weight Loss

Resumen Hoy disponemos de herramientas eficaces para tratar la obesidad: desde frmacos como semaglutida o tirzepatida hasta el baln intragstrico

Questions to consider include Should my bariatric or metabolic surgery team be involved How does my surgical anatomy affect medication tolerance and dosing Are there nutritional risks that need closer monitoring How does this fit into my long term post surgical care plan Clinical guidance from the American Society for Metabolic and Bariatric Surgery emphasizes lifelong multidisciplinary follow up after bariatric surgery, particularly when additional pharmacologic therapies such as Obesity Management Medications are introduced

8 Endogenous glucagon-like peptide-1 (GLP-1) is a peptide secreted from intestinal L cells and neurons in the nucleus tractus solitarius of the caudal brainstem

Some formulas exclude iron (often by design), and calcium is frequently omitted or included in smaller amounts

For currently approved GLP-1 receptor agonists available for weight management in the UK, NICE has established specific eligibility criteria: Semaglutide (Wegovy) NICE TA875 recommends semaglutide for adults with: A body mass index (BMI) of 35 kg/m or above with at least one weight-related comorbidity (such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity, prescribed only in specialist weight management services Evidence of previous unsuccessful weight loss attempts through diet, physical activity, and behavioural interventions Treatment is limited to a maximum of 2 years Liraglutide (Saxenda) NICE TA664 recommends liraglutide for adults with: A BMI of 35 kg/m or above (with or without comorbidities), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity Evidence of previous unsuccessful weight loss attempts Treatment is limited to a maximum of 2 years Both medications must be prescribed as part of a specialist weight management service providing multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions

The proposed mechanism involves inhibition of the NF-kB pathway, a master regulator of inflammatory gene expression